3SBio Inc.

Shenyang 3SBio Pharmaceutical Co., Ltd. (hereinafter referred to as 3SBio) was established in 1993. Its business scope is: research, development, production and sales of bioengineering products and biochemical drugs, as well as technical services for after-sales products. The Chinese name of the company is "Sansheng", and the entrepreneurs hope to inspire themselves with the lofty belief of "cherishing life, paying attention to survival, and creating life"; the English name of the company is SUNSHINE, which means "sunshine" and entrusts Sansheng people with the "sunshine-like" belief. The great ideal of serving patients and benefiting human society with "warmth and enthusiasm". The company is a technology enterprise recognized by the Shenyang Science and Technology Bureau and the Liaoning Provincial Science and Technology Department. In 1999, it was recognized as a national key technology enterprise by the Ministry of Science and Technology, and in 2001, it was recognized as an "Industrialization Base for National High-Tech Research and Development (863) Program Achievements" by the Ministry of Science and Technology. The company's production plant is located in Shenyang Economic and Technological Development Zone, covering an area of ​​48,000 square meters and a building area of ​​10,000 square meters. It includes three workshops: bacterial genetic engineering pharmaceuticals, cell genetic engineering pharmaceuticals and preparation packaging. All production workshops have passed the national food GMP certification from the Drug Administration (SFDA). The annual production capacity reaches more than 10 million units, forming a professional biopharmaceutical base with a relatively large production scale in China. At present, the company has completed the research and development of four genetic engineering products. The company's research institute has strong product and technology development capabilities and has formed an excellent new product research and development system. It has successively undertaken two National Torch Plan projects and one "863" plan project, and has won many awards from national ministries, provincial and municipal governments. Departmental research awards. Currently, the company has a total of 6 national invention patents that have been authorized or are in the process of application. Sansheng Company has implemented a comprehensive market cultivation and development strategy while pursuing economies of scale and continuously reducing production costs and product prices. At present, more than 20 sales offices have been set up across the country, with a professional and high-quality marketing team, building an efficient and orderly sales network focusing on large and medium-sized cities, economically developed regions and large and medium-sized hospitals across the country. , sales performance has grown steadily, and brand benefits have continued to increase. On February 7, 2007, 3SBio was listed on NASDAQ in the United States, becoming the first Chinese biotechnology and pharmaceutical company to be directly listed on NASDAQ and the largest biotechnology IPO in the United States in the past three years. . As a domestic leader in the field of biopharmaceuticals, 3SBio will continue to maintain its leading domestic position in production, R&D, and marketing through unremitting efforts, and will make full use of our superior financial channels and good commercial operations to expand The company expanded its scale and opened up the international market, and then developed into an internationally renowned biopharmaceutical company. As the pioneer of China's genetic pharmaceuticals, Sansheng people are shouldering the important task of awakening people's confidence in recovery and awareness of life, and are willing to use their own light and enthusiasm to support the sunrise of China's genetic pharmaceuticals as soon as possible!